CD8+与CD4+T-LGL白血病的转录组图谱揭示STAT3与STAT5B激活突变的差异性影响
研究通过对纯化T-LGL进行RNA测序,揭示CD8+或CD4+表型及STAT3/STAT5B突变状态定义的主要患者亚组的基因表达谱和通路失调。T-LGLL患者转录组显著失调,以CD8+STAT3突变型最明显,表现为增殖和细胞周期通路去抑制;STAT5B突变对转录组影响较有限,PIM1过表达是STAT5B突变CD4+T-LGLL的重要特征。
要点
- CD8+STAT3突变型T-LGLL呈现广泛基因下调,导致增殖和细胞周期通路去抑制。
- CD8+STAT3突变型中VCAM1、EZH2、MDM2及PVT1上调,为白血病T-LGL中长非编码RNA改变的首次报告。
- STAT5B突变对T-LGL转录组影响较有限,PIM1过表达是STAT5B突变CD4+T-LGLL的重要特征。
核心结论
- T-LGLL患者转录组显著失调,CD8+STAT3突变型构成独特生物学实体,STAT5B突变影响较有限。
研究设计与样本
- 对纯化T-LGL进行RNA测序,按CD8+或CD4+表型及STAT3/STAT5B突变状态分组分析基因表达谱和通路失调。
主要发现
- T-LGLL患者较对照呈现显著转录组失调,以CD8+STAT3突变型最明显。
- CD8+STAT3突变型显示广泛基因下调,导致增殖和细胞周期通路去抑制。
- CD8+STAT3突变型中VCAM1、EZH2、MDM2及PVT1上调,为白血病T-LGL中长非编码RNA改变的首次报告。
- STAT5B突变对T-LGL转录组影响较有限,PIM1过表达是STAT5B突变CD4+T-LGLL的重要特征之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The biological basis of the high clinical heterogeneity of T-LGL Leukemia (T-LGLL) is not completely understood and effective therapies for this disease are lacking. Through RNA-Sequencing of purified T-LGLs we reveal gene expression profiles and pathway dysregulations in the major patient subgroups, defined by CD8+ or CD4+ phenotype and STAT3/STAT5B mutational status. Overall, T-LGLL patients exhibited a marked transcriptome dysregulation compared to controls. This was more pronounced in the most symptomatic CD8 + STAT3-mutated patients, which emerged as a distinct biological entity, separated from the other disease subgroups. Particularly, CD8 + STAT3-mutated cases displayed extensive down-regulation of genes, ultimately resulting in the de-repression of proliferation and cell cycle pathways. Among genes up-regulated in CD8 + STAT3-mutated cases we found VCAM1, the transcriptional repressor EZH2 and the p53-regulator MDM2 proto-oncogene, as well as the leukemogenesis-associated PVT1 up-regulation, representing the first report of a long-non-coding RNA alterations in leukemic T-LGLs. The impact of STAT5B mutations on T-LGLs transcriptome was more limited and the overexpression of the PIM1 serine/threonine kinase proto-oncogene was identified as one of the most relevant features of STAT5B-mutated CD4 + T-LGLL. This study significantly advances our understanding of T-LGLL pathogenesis, uncovering new oncogenic mechanisms within the distinct molecular subtypes of the disease.
引用
- Calabretto G, Binatti A, Teramo A, et al. Transcriptomic landscape of CD8+ and CD4 + T-LGL leukemia revealed the distinct impact of STAT3 and STAT5B activating mutations. Leukemia. 2025. PMID: 40721648. doi:10.1038/s41375-025-02708-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。